Evidence map›Paper›PMID 38987361›Full record

ArticleJournal of molecular neuroscience : MN2024

Exploratory Mass Spectrometry of Cerebrospinal Fluid from Persons with Autopsy-Confirmed LATE-NC.

Jozsef Gal, Calvin Vary, Carlos A Gartner, Gregory A Jicha, Erin L Abner, Yulica S Ortega, Ibrahim Choucair, Donna M Wilcock, Ruth S Nelson, Peter T Nelson

Abstract read
In one paragraph

Article in Journal of molecular neuroscience : MN, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

Jozsef GalSpinal Cord and Brain Injury Research Center (SCoBIRC), University of Kentucky, Lexington, KY, USA.
Calvin VaryCenter for Molecular Medicine, MaineHealth Institute for Research, Scarborough, ME, USA.
Carlos A GartnerCenter for Molecular Medicine, MaineHealth Institute for Research, Scarborough, ME, USA.
Gregory A JichaSanders-Brown Center On Aging, University of Kentucky, Lexington, KY, USA.
Erin L AbnerSanders-Brown Center On Aging, University of Kentucky, Lexington, KY, USA.
Yulica S OrtegaCenter for Molecular Medicine, MaineHealth Institute for Research, Scarborough, ME, USA.
Ibrahim ChoucairDepartment of Pathology and Laboratory Medicine, University of Kentucky, Rm 575 Todd Building, Lexington, KY, 40536, USA.
Donna M WilcockSanders-Brown Center On Aging, University of Kentucky, Lexington, KY, USA.
Ruth S NelsonYale University, New Haven, CT, USA.
Peter T NelsonSanders-Brown Center On Aging, University of Kentucky, Lexington, KY, USA. pnels2@email.uky.edu.

Funding

University of Kentucky Alzheimer's Disease Research CenterP30AG072946 · NIA · UNIVERSITY OF KENTUCKY · PI LINDA J VAN ELDIK · 2021 to 2026
$23.5M
Role of impaired cognitive states & risk factors in conversion to mixed dementiasR01AG038651 · NIA · UNIVERSITY OF KENTUCKY · PI ABNER, ERIN, KRYSCIO, RICHARD J. · 2011 to 2023
$6.1M
Genetic Architecture of Pure Alzheimer's Disease and Mixed PathologyR01AG082730 · NIA · UNIVERSITY OF WASHINGTON · PI David William Fardo, Shubhabrata Mukherjee · 2023 to 2026
$4.0M
Safety and modulation of ABCC9 pathways by nicorandil for the treatment of hippocampal sclerosis of aging (SMArT–HS)R01AG061111 · NIA · UNIVERSITY OF KENTUCKY · PI JICHA, GREGORY A, NELSON, PETER T. · 2019 to 2025
$3.6M
Age-related TDP-43 neuropathology: using disease-driving mechanisms to guide classificationRF1NS118584 · NINDS · METHODIST HOSPITAL RESEARCH INSTITUTE · PI CYKOWSKI, MATTHEW DANIEL, NELSON, PETER T. · 2020 to 2020
$3.2M
Genetic Architecture of Aging-Related TDP-43 and Mixed Pathology DementiaRF1AG082339 · NIA · UNIVERSITY OF KENTUCKY · PI FARDO, DAVID WILLIAM, NELSON, PETER T. · 2023 to 2023
$1.7M
Age-related TDP-43 neuropathology: using disease-driving mechanisms to guide classificationR01NS118584 · NINDS · METHODIST HOSPITAL RESEARCH INSTITUTE · PI CYKOWSKI, MATTHEW DANIEL, NELSON, PETER T. · 2024 to 2024
$791k
NIA NIH HHS P30 AG072946NIA NIH HHS R01 AG038651NIA NIH HHS R01 AG061111NIA NIH HHS R01 AG082730NIA NIH HHS RF1 AG082339NIH HHS R01 AG061111NINDS NIH HHS R01 NS118584NINDS NIH HHS RF1 NS118584
6 · The paper itself

Abstract

Common neuropathologies associated with dementia include Alzheimer's disease neuropathologic change (ADNC) and limbic-predominant age-related TDP-43 encephalopathy neuropathologic change (LATE-NC). Biofluid proteomics provides a window into the pathobiology of dementia and the information from biofluid tests may help guide clinical management. Participants (n = 29) had been autopsied and had antemortem CSF draws in a longitudinal cohort of older adults at the University of Kentucky AD Research Center. Cases were designated as LATE-NC + if they had LATE-NC stage > 1 (n = 9); the remaining 20 cases were designated LATE-NC-. This convenience sample of CSF specimens was analyzed in two separate processes: From one group, aliquots were depleted of highly abundant proteins using affinity spin columns. Tryptic digests of sample proteins were subjected to liquid chromatographic separation and mass spectrometry. Relative quantification was performed using Sciex software. Peptides referent to a total of 949 proteins were identified in the samples depleted of abundant proteins, and 820 different proteins were identified in the non-depleted samples. When the Bonferroni/false-discovery statistical correction was applied to account for having made multiple comparison tests, only 4 proteins showed differential expression (LATE-NC + vs LATE-NC-) in the non-depleted samples (RBP4, MIF, IGHG3, and ITM2B). Post hoc western blots confirmed that RBP4 expression was higher in the LATE-NC + cases at the group level. In summary, an exploratory assessment of proteomes of autopsy-confirmed LATE-NC and non-LATE-NC CSF did not demonstrate a clear-cut proteomic fingerprint that distinguished the two groups. There was, however, an increase in RBP4 protein levels in CSF from LATE-NC cases.

Indexed as

BiomarkersAgedAged, 80 and overAlzheimer DiseaseDementiaFemaleHumansMaleProteomeRetinol-Binding Proteins, PlasmaTDP-43 ProteinopathiesBiomarkersProteomeRBP4 protein, humanRetinol-Binding Proteins, PlasmaAdipokineAgingBiomarkerBRI2CNDP1RET4

Identifiers

PMID38987361
PMCPMC12038453

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.